Eevia Health Plc

Logotype for Eevia Health Plc
Ticker/ISIN
EEVIA
FI4000496658
Marknad/Land
SE
Sweden

Senaste sammanfattade pressmeddelande från Eevia Health Plc

Eevia Health PLC has received sales orders totaling 54,000 euros from European and Asian customers following the BIOFACH 2025 trade fair. The orders include products such as Feno-Myrtillus™ 36 and Fenoprolic™ Full Spectrum from German customers, a tart cherry extract from Australia, and Feno-Myrtillus 25 from Taiwan. Eevia has the products in stock, allowing for immediate delivery, which is beneficial for cash flow. These are repeat orders, with expectations for further orders from these customers. Eevia Health, established in 2017, produces bioactive plant extracts for global dietary supplements and food brands, focusing on sustainable and environmentally friendly practices. The company is listed on the Spotlight Stock Market in Sweden.
Eevia Health Plc will participate in BIOFACH, a leading trade fair for organic food, from February 11 to 14 in Nuremberg, Germany. The company will promote its organic products in collaboration with its distribution partner BREKO in the DACH countries. Eevia Health, founded in 2017, produces bioactive compounds from renewable plant materials, focusing on gut and related health areas. Their extracts, primarily sourced from Finnish and Swedish forests, are used in dietary supplements and food brands globally. Eevia operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.
Eevia Health Plc has concluded mandatory cooperation negotiations concerning organizational restructuring and downsizing. The company, which employs 19 people, is reducing its workforce: six employees will leave voluntarily (two resigning and four moving to new roles linked to divested assets), two will shift to part-time, and four employment contracts will be terminated. Eevia will retain nine key employees, with expected annual salary savings of KEUR 490. The changes, effective starting February 2025, are intended to improve cost efficiency. They are expected to positively affect operating costs as early as Q1 2024. Despite the reduced staff size, Eevia aims to maintain the core competencies necessary to reach its 2025 revenue target of MEUR 3 and to scale up as future growth opportunities arise. Based on its updated strategy, Eevia will focus on developing proanthocyanidin-based gut health solutions. This shift will result in a different staffing profile, placing greater emphasis on sales, marketing, and product management. Downsizing is intended to restore profitability and align the workforce with Eevia’s business goals, while laying a foundation for growth through scientifically supported botanical solutions. Eevia, founded in 2017, specializes in producing organically certified plant extracts from sustainably harvested materials gathered near or above the Arctic Circle. It supplies these extracts globally for use in dietary supplements and foods, and also develops high-value ingredients and blended solutions. Eevia’s environmentally conscious approach includes a modern production facility and a short value chain. Its shares are listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.
Eevia Health is hosting two digital investor webinars to provide updates on its strategic reorientation and current rights issue. These webinars are scheduled for February 10 and February 14, 2025, and will be conducted via Microsoft Teams. The sessions will be led by CEO Stein Ulve, CTO Petri Lackman, and Commercial Director Erik Eide. Eevia Health, founded in 2017, focuses on producing bioactive compounds from renewable plant materials for global health challenges, specifically targeting gut, kidney, and urinary health. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.
Eevia Health Plc has agreed to sell the intellectual property related to its lead eye-health compound, Retinari™, to Havu Health Oy for KEUR 800. Retinari™, derived from pine wood, has shown promising pre-clinical results in combating Age-related Macular Degeneration (AMD), a leading cause of blindness. Despite strong interest and top scores in international funding competitions, Eevia did not secure necessary funding for human safety studies, limiting the project's progression. Consequently, the inventors, including Eevia's CTO Petri Lackman, sought commercialization rights outside Eevia. Eevia agreed to sell the intellectual property to Havu Health Oy, a startup founded by Lackman, which plans to commercialize the product and seek development funding. Eevia will receive shares in Havu Health Oy as payment. The transaction is subject to third-party assessment and creditor consent. Eevia Health focuses on bioactive compounds from renewable plant materials and operates a green-chemistry facility in Finland.
Eevia Health Plc has announced that the publication of its Q4 2024 interim report will be moved up to February 4, 2025, from the originally scheduled date of February 14, 2025. This change aims to allow insiders, who are currently restricted by a trading ban, to participate in the ongoing rights issue. As a result, the subscription period for the rights issue has been extended by one week to give investors more time to consider their investments. The updated timetable for the rights issue includes specific trading and subscription periods for Sweden and Finland. Eevia Health, founded in 2017, produces bioactive compounds from renewable plant materials and operates a green-chemistry production facility in Finland. The company's shares are listed on the Spotlight Stock Market in Sweden. The press release emphasizes that it does not constitute an offer to trade securities in jurisdictions where such actions would violate laws and highlights that no prospectus will be prepared for the rights issue.
Eevia Health PLC has announced a strategic reorientation and a rights issue of shares totaling approximately SEK 12.1 million, as decided by the board on January 17, 2025. An investment teaser detailing the company's business, products, strategy, and the rights issue is available on Eevia Health's website. The rights issue will involve trading in subscription rights from January 28 to February 6, 2025, with subscription periods in Sweden and Finland from January 28 to February 11 and January 29 to February 13, respectively. The estimated date for announcing the outcome of the rights issue is February 17, 2025. Eevia Health, founded in 2017, focuses on developing bioactive compounds from renewable plant materials for health areas such as gut, kidney, and urinary health. The company's plant extracts are sold globally as ingredients to dietary supplements and food brands. Eevia Health operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or contact CEO Stein Ulve.
Eevia Health Plc has initiated a rights issue to raise approximately SEK 12.1 million, with the subscription period running from 28 January to 11 February 2025 in Sweden and 29 January to 13 February 2025 in Finland. The rights issue offers existing shareholders preferential rights to subscribe to new shares, with a subscription price of SEK 0.09 per share. The company aims to use the funds to repay debt, support working capital, and invest in product research and development. The rights issue is part of a broader strategic plan, including product diversification towards gut, kidney, and urinary health, and divestments of certain assets to new start-ups, Havu Health Oy and Baccus Salas Oy. These divestments aim to streamline operations and focus on higher-margin, scientifically substantiated products. Eevia is also negotiating with creditors to extend debt maturity and stabilize its financial position. The company plans to continue as a specialized provider of bioactive compounds, targeting global health challenges.

Threads

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc receives multiple sales orders for c. KSEK 1 045 (KEUR 90)

Eevia Health has received multiple orders for its pine bark, bilberry, and lingonberry extracts, totaling KSEK 1 045 (KEUR 90) from various European and Australian customers. The orders include Fenoprolic 70 Organic (Pine bark extract), Feno-Myrtillus 25 Organic (Bilberry Extract), and Lingonberry Extract with Acacia. These orders are from several European customers with consumer brands in foods, drinks, and supplements, as well as an order for a pet food company and an Australian company. The company expects further repeat orders from the same customers in the future. Eevia Health is a manufacturer of 100% organically certified plant extracts, primarily wild harvested from Finnish and Swedish forests.

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc receives multiple sales orders for c. KSEK 518 (KEUR 50)

Eevia Health has received multiple sales orders from various European customers, totaling approximately 518 kSEK or 50 kEUR. The orders are for a range of products including Chaga extract, bilberry extracts, and Pine bark extract, and came from Finnish and European customers in the whole foods, drinks, and supplement sectors. The company, which has the products in stock, anticipates more repeat orders from the same customers. Eevia Health, established in 2017, is a manufacturer of 100% organically certified plant extracts, primarily harvested from Finnish and Swedish forests. The company listed its shares on the Spotlight Stock Market in Sweden in 2021.

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc finalizes a key development project and receives grant payment for c. 2,747 KSEK (243 KEUR)

Eevia Health has completed a project documenting the bioactivity of its products, co-funded by Business Finland. The project, which was conducted in 2023 and reported in February 2024, involved extensive in vitro testing of Eevia's top extracts. The study yielded promising results, particularly for one ingredient. The company is now planning a follow-up project, "Global Vision", for this ingredient and is seeking approximately €800k in non-dilutive funding. The project aims to bring the product to market for human use. Eevia Health, which manufactures organically certified plant extracts, primarily sources its materials from the forests of Finland and Sweden.

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc receives a KSEK 1,472 (KUSD 142) sales order for Feno-Sambucus™ 7 Organic

Eevia Health has received a blanket sales order worth 1,472 kSEK / 142 kUSD for its elderberry extract product, Feno-Sambucus™ 7 Organic, from US distributor Select Ingredients. The order will be fulfilled over several months and is a repeat order from an end customer in the whole foods and drinks sector, which is experiencing rapid growth. Eevia Health expects further repeat orders in the future. The company, which was founded in 2017, extracts bioactive compounds from plant materials, primarily harvested from Finnish and Swedish forests. It operates a green-chemistry production facility in Finland and listed its shares on the Spotlight Stock Market in Sweden in June 2021.

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc revises its Information Policy

Eevia Health Plc has updated its Information Policy and increased the threshold for sales orders and contracts that warrant a press release from 10 KEUR to 50 KEUR. The change is in response to criticism from investors who felt the company was providing too much information about smaller orders. The company will also issue a press release when several smaller orders accumulate to a value over 50 KEUR. Eevia Health Plc, a manufacturer of organically certified plant extracts, was founded in 2017 and listed its shares on the Spotlight Stock Market in Sweden in 2021.

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Report: Eevia Health Plc Year End Report - 2023

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc engages with a global market leader to evaluate collaboration on the launch of a novel dietary eye-health ingredient

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc has secured a credit line of SEK 7.2 million for working capital purposes to finance continued growth

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc received a 445 KSEK / 39 KEUR sales order for a Bilberry extract

1. Bifogad dokument

SE News profile image

SE News

Nyhetsuppdatering från Eevia Health Plc

Press Release: Eevia Health Plc received a 159 KSEK / 14 KEUR sales order for a pine bark extract product

1. Bifogad dokument